Imagining the cell therapist: Future CAR T cell monitoring and intervention strategies to improve patient outcomes

por Jain, Michael D., Spiegel, Jay Y.
Publicado 2021

How I treat refractory CRS and ICANS after CAR T-cell therapy

por Jain, Michael D., Smith, Melody, Shah, Nirali N.
Publicado 2023

Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma

por Jain, Michael D, Bachmeier, Christina A, Phuoc, Vania H, Chavez, Julio C
Publicado 2018

Case of Myocarditis After Chimeric Antigen Receptor T Cells With Intracardiac Lymphoma

por Lee, Dae Hyun, Jain, Michael, Lazaryan, Aleksandr, Locke, Frederick L., Jeong, Daniel, Alomar, Mohammed
Publicado 2022

SubID, a non-median dichotomization tool for heterogeneous populations, reveals the pan-cancer significance of INPP4B and its regulation by EVI1 in AML

por Dzneladze, Irakli, Woolley, John F., Rossell, Carla, Han, Youqi, Rashid, Ayesha, Jain, Michael, Reimand, Jüri, Minden, Mark D., Salmena, Leonardo
Publicado 2018

Repeatability of metabolic tumor burden and lesion glycolysis between clinical readers

por Choi, Jung W., Dean, Erin A., Lu, Hong, Thompson, Zachary, Qi, Jin, Krivenko, Gabe, Jain, Michael D., Locke, Frederick L., Balagurunathan, Yoganand
Publicado 2023

Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma

por Sheikh, Semira, Mokhtari, Sepideh, Silverman, Jeffrey A., Reid, Kayla, Faramand, Rawan, Davila, Marco L., Franke, Norman, Locke, Frederick L., Jain, Michael D., Wong, Daniel, Kuruvilla, John G.
Publicado 2021

Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma

por Dean, Erin A., Kimmel, Gregory J., Frank, Matthew J., Bukhari, Ali, Hossain, Nasheed M., Jain, Michael D., Dahiya, Saurabh, Miklos, David B., Altrock, Philipp M., Locke, Frederick L.
Publicado 2023

Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

por Jain, Michael D., Miklos, David B., Jacobson, Caron A., Timmerman, John M., Sun, Jennifer, Nater, Jenny, Fang, Xiang, Patel, Ankit, Davis, Madison, Heeke, Darren, Trinh, Tan, Mattie, Mike, Neumann, Frank, Kim, Jenny J., To, Christina, Filosto, Simone, Reshef, Ran
Publicado 2023

Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL

por Perez, Ariel, Johnson, Grace, Patel, Kedar, Arciola, Brian, Wood, Anthony, Bachmeier, Christina A., Chavez, Julio C., Shah, Bijal D., Khimani, Farhad, Nishihori, Taiga, Lazaryan, Aleksandr, Davila, Marco L., Mhaskar, Rahul, Locke, Frederick L., Gaballa, Sameh, Jain, Michael D.
Publicado 2022

Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy

por Rejeski, Kai, Cordas dos Santos, David M., Parker, Nathan H., Bücklein, Veit L., Winkelmann, Michael, Jhaveri, Khushali S., Liu, Lian, Trinkner, Paul, Günther, Sophie, Karschnia, Philipp, Blumenberg, Viktoria, Schmidt, Christian, Kunz, Wolfgang G., von Bergwelt-Baildon, Michael, Jain, Michael D., Theurich, Sebastian, Subklewe, Marion
Publicado 2023

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma

por Rejeski, Kai, Hansen, Doris K., Bansal, Radhika, Sesques, Pierre, Ailawadhi, Sikander, Logue, Jennifer M., Bräunlein, Eva, Cordas dos Santos, David M., Freeman, Ciara L., Alsina, Melissa, Theurich, Sebastian, Wang, Yucai, Krackhardt, Angela M., Locke, Frederick L., Bachy, Emmanuel, Jain, Michael D., Lin, Yi, Subklewe, Marion
Publicado 2023

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

por Rejeski, Kai, Perez, Ariel, Iacoboni, Gloria, Penack, Olaf, Bücklein, Veit, Jentzsch, Liv, Mougiakakos, Dimitrios, Johnson, Grace, Arciola, Brian, Carpio, Cecilia, Blumenberg, Viktoria, Hoster, Eva, Bullinger, Lars, Locke, Frederick L, von Bergwelt-Baildon, Michael, Mackensen, Andreas, Bethge, Wolfgang, Barba, Pere, Jain, Michael D, Subklewe, Marion
Publicado 2022

P1540: COVID-19 INFECTION AMONG CAR-T CELL THERAPY RECIPIENTS: A SINGLE CENTER EXPERIENCE

por Din, Mohammad Ammad Ud, Oh, Nayeon, Baluch, Aliyah, Klinkova, Olga, Quilitz, Rod, Alsina, Melissa, Bejanyan, Nelli, Castaneda, Omar, Chavez, Julio, Elmariah, Hany, Freeman, Ciara, Hansen, Doris, Jain, Michael, Khimani, Farhad, Lazaryan, Aleksandr, Liu, Hien, Mishra, Asmita, Ochoa, Leonel, Perez, Lia, Pidala, Joseph, Shah, Bijal, Nishihori, Taiga, Locke, Frederick, Faramand, Rawan
Publicado 2023

Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study

por Lee, Dae Hyun, Chandrasekhar, Sanjay, Jain, Michael D., Mhaskar, Rahul, Reid, Kayla, Lee, Sae Bom, Corallo, Salvatore, Hidalgo-Vargas, Melanie J., Kumar, Abhishek, Chavez, Julio, Shah, Bijal, Lazaryan, Aleksandr, Khimani, Farhad, Nishihori, Taiga, Bachmeier, Christina, Faramand, Rawan, Fradley, Michael G., Jeong, Daniel, Oliveira, Guilherme H., Locke, Frederick L., Davila, Marco L, Alomar, Mohammed
Publicado 2023

Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma

por Scholler, Nathalie, Perbost, Regis, Locke, Frederick L., Jain, Michael D., Turcan, Sarah, Danan, Corinne, Chang, Edmund C., Neelapu, Sattva S., Miklos, David B., Jacobson, Caron A., Lekakis, Lazaros J., Lin, Yi, Ghobadi, Armin, Kim, Jenny J., Chou, Justin, Plaks, Vicki, Wang, Zixing, Xue, Allen, Mattie, Mike, Rossi, John M., Bot, Adrian, Galon, Jérôme
Publicado 2022

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammatio...

por Bücklein, Veit, Perez, Ariel, Rejeski, Kai, Iacoboni, Gloria, Jurinovic, Vindi, Holtick, Udo, Penack, Olaf, Kharboutli, Soraya, Blumenberg, Viktoria, Ackermann, Josephine, Frölich, Lisa, Johnson, Grace, Patel, Kedar, Arciola, Brian, Mhaskar, Rahul, Wood, Anthony, Schmidt, Christian, Albanyan, Omar, Gödel, Philipp, Hoster, Eva, Bullinger, Lars, Mackensen, Andreas, Locke, Frederick, von Bergwelt, Michael, Barba, Pere, Subklewe, Marion, Jain, Michael D.
Publicado 2023

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion

por Rejeski, Kai, Perez, Ariel, Iacoboni, Gloria, Blumenberg, Viktoria, Bücklein, Veit L., Völkl, Simon, Penack, Olaf, Albanyan, Omar, Stock, Sophia, Müller, Fabian, Karschnia, Philipp, Petrera, Agnese, Reid, Kayla, Faramand, Rawan, Davila, Marco L., Modi, Karnav, Dean, Erin A., Bachmeier, Christina, von Bergwelt-Baildon, Michael, Locke, Frederick L, Bethge, Wolfgang, Bullinger, Lars, Mackensen, Andreas, Barba, Pere, Jain, Michael D., Subklewe, Marion
Publicado 2023

Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel

por Hoogland, Aasha I., Jayani, Reena V., Collier, Aaron, Irizarry‐Arroyo, Nathaly, Rodriguez, Yvelise, Jain, Michael D., Booth‐Jones, Margaret, Hyland, Kelly A., James, Brian W., Barata, Anna, Bachmeier, Christina A., Chavez, Julio C., Khimani, Farhad, Krivenko, Gabriel S., Lazaryan, Aleksandr, Liu, Hien D., Nishihori, Taiga, Pinilla‐Ibarz, Javier, Shah, Bijal D., Abidi, Muneer, Locke, Frederick L., Jim, Heather S. L.
Publicado 2021

Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma

por Logue, Jennifer M., Zucchetti, Elisa, Bachmeier, Christina A., Krivenko, Gabriel S., Larson, Victoria, Ninh, Daniel, Grillo, Giovanni, Cao, Biwei, Kim, Jongphil, Chavez, Julio C., Baluch, Aliyah, Khimani, Farhad, Lazaryan, Aleksandr, Nishihori, Taiga, Liu, Hien D., Pinilla-Ibarz, Javier, Shah, Bijal D., Faramand, Rawan, Coghill, Anna E., Davila, Marco L., Dholaria, Bhagirathbhai R., Jain, Michael D., Locke, Frederick L.
Publicado 2020